Atorvastatin

Generic Name
Atorvastatin
Brand Names
Atorvaliq, Caduet, Lipitor, Lypqozet
Drug Type
Small Molecule
Chemical Formula
C33H35FN2O5
CAS Number
134523-00-5
Unique Ingredient Identifier
A0JWA85V8F
Background

Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication

Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions
Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
Associated Therapies
-
Clinical Trials
Related News

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

Phase 4
Completed
Conditions
Cardiovascular Disease
First Posted Date
2005-09-07
Last Posted Date
2015-04-22
Lead Sponsor
Pfizer
Target Recruit Count
4732
Registration Number
NCT00147602
Locations
🇻🇪

Pfizer Investigational Site, Caracas, Venezuela

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Phase 3
Terminated
Conditions
Hyperlipoproteinemia Type III
First Posted Date
2005-09-05
Last Posted Date
2012-02-17
Lead Sponsor
Pfizer
Target Recruit Count
41
Registration Number
NCT00145431
Locations
🇨🇦

Pfizer Investigational Site, Quebec, Canada

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

First Posted Date
2005-09-02
Last Posted Date
2012-05-24
Lead Sponsor
Takeda
Target Recruit Count
448
Registration Number
NCT00143676

Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia

Phase 4
Completed
Conditions
Hypercholesterolemia
First Posted Date
2005-09-01
Last Posted Date
2021-02-18
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
383
Registration Number
NCT00141141
Locations
🇮🇹

Pfizer Investigational Site, Udine, Italy

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

Phase 3
Completed
Conditions
Hyperlipidemia
First Posted Date
2005-08-30
Last Posted Date
2012-02-17
Lead Sponsor
Pfizer
Target Recruit Count
3800
Registration Number
NCT00138762
Locations
🇬🇧

Pfizer Investigational Site, Warminster, Wiltshire, United Kingdom

A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Phase 3
Completed
Conditions
Hyperlipidemia
First Posted Date
2005-08-29
Last Posted Date
2021-02-18
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
370
Registration Number
NCT00136942
Locations
🇨🇭

Pfizer Investigational Site, Zuerich, ZH, Switzerland

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

Phase 3
Completed
Conditions
Hyperlipidemia
First Posted Date
2005-08-29
Last Posted Date
2007-11-16
Lead Sponsor
Pfizer
Target Recruit Count
900
Registration Number
NCT00137462
Locations
🇨🇦

Pfizer Investigational Site, St. Georges de Beauce, Quebec, Canada

Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.

First Posted Date
2005-08-29
Last Posted Date
2015-04-22
Lead Sponsor
Pfizer
Target Recruit Count
800
Registration Number
NCT00136981
Locations
🇿🇦

Pfizer Investigational Site, Cape Town, South Africa

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

Phase 3
Terminated
Conditions
Mixed Hyperlipidemia
First Posted Date
2005-08-24
Last Posted Date
2012-02-17
Lead Sponsor
Pfizer
Target Recruit Count
755
Registration Number
NCT00134238
Locations
🇳🇱

Pfizer Investigational Site, Utrecht, Netherlands

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

Phase 3
Terminated
Conditions
Diabetes Mellitus
Coronary Disease
First Posted Date
2005-08-24
Last Posted Date
2012-02-03
Lead Sponsor
Pfizer
Target Recruit Count
15067
Registration Number
NCT00134264
Locations
🇬🇧

Pfizer Investigational Site, Warwick, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy